{'fraction_non_alphanumeric': 0.019305019305019305, 'fraction_numerical': 0.0023166023166023165, 'mean_word_length': 5.8936170212765955, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Dependence of clinical and laboratory indicators of the level of systemic inflammation in patients with psoriasis of moderate severity with concomitant metabolic syndrome].

The purpose of this study is to establish the relationship between clinical and laboratory indicators of the level of systemic inflammation in patients with psoriasis with concomitant metabolic syndrome. Clinical and laboratory studies conducted in 40 patients with uncomplicated common plaque psoriasis, the stationary stage, the average degree of severity with concomitant metabolic syndrome. There is a clear relationship between the level of hs-CRP and indices PASI, BSA, BMI, SAT, insulin, HOMA, IL-6, TNF-α and ceruloplasmin. This indicates the relationship between the severity of psoriasis, metabolic disorders and systemic inflammation. Systemic inflammatory process is accompanied by insulin resistance, disorders of lipid and nitrogen metabolism and regulation of vascular tone. Increase in the intensity of systemic inflammation is accompanied by increased skin lesions, increased systolic blood pressure and disorders of lipid and carbohydrate metabolism. Processes of systemic inflammation andinsulin resistance in patients with psoriasis and metabolic syndrome may be potential targets of complex therapy.